CO5631449A2 - Nuevos esteres de etonogestrel - Google Patents
Nuevos esteres de etonogestrelInfo
- Publication number
- CO5631449A2 CO5631449A2 CO04127949A CO04127949A CO5631449A2 CO 5631449 A2 CO5631449 A2 CO 5631449A2 CO 04127949 A CO04127949 A CO 04127949A CO 04127949 A CO04127949 A CO 04127949A CO 5631449 A2 CO5631449 A2 CO 5631449A2
- Authority
- CO
- Colombia
- Prior art keywords
- etonogestrel
- hrt
- contraception
- decanoate
- undecanoate
- Prior art date
Links
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical class O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 title abstract 7
- 229960002941 etonogestrel Drugs 0.000 abstract 8
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract 3
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 abstract 3
- 239000003433 contraceptive agent Substances 0.000 abstract 2
- 230000002254 contraceptive effect Effects 0.000 abstract 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077119 | 2002-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5631449A2 true CO5631449A2 (es) | 2006-04-28 |
Family
ID=29595014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04127949A CO5631449A2 (es) | 2002-05-30 | 2004-12-22 | Nuevos esteres de etonogestrel |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7323454B2 (https=) |
| EP (1) | EP1513861B1 (https=) |
| JP (1) | JP4716726B2 (https=) |
| KR (1) | KR20050009723A (https=) |
| CN (2) | CN1314701C (https=) |
| AR (1) | AR040130A1 (https=) |
| AT (1) | ATE349458T1 (https=) |
| AU (1) | AU2003238081B2 (https=) |
| BR (1) | BR0311254A (https=) |
| CA (1) | CA2487722C (https=) |
| CO (1) | CO5631449A2 (https=) |
| DE (1) | DE60310714T2 (https=) |
| DK (1) | DK1513861T3 (https=) |
| ES (1) | ES2277085T3 (https=) |
| HR (1) | HRP20041101A2 (https=) |
| IL (1) | IL165087A0 (https=) |
| IS (1) | IS2421B (https=) |
| MX (1) | MXPA04011797A (https=) |
| NO (1) | NO20044898L (https=) |
| NZ (1) | NZ536619A (https=) |
| PE (1) | PE20040068A1 (https=) |
| PL (1) | PL373855A1 (https=) |
| PT (1) | PT1513861E (https=) |
| RS (1) | RS97604A (https=) |
| RU (1) | RU2325910C2 (https=) |
| SI (1) | SI1513861T1 (https=) |
| TW (1) | TW200403065A (https=) |
| UA (1) | UA80126C2 (https=) |
| WO (1) | WO2003102012A2 (https=) |
| ZA (1) | ZA200410410B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400041A (en) * | 2002-05-30 | 2004-01-01 | Akzo Nobel Nv | Use of new etonogestrel esters |
| WO2007011707A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
| WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
| ES2540059T3 (es) | 2006-04-26 | 2015-07-08 | Micell Technologies, Inc. | Recubrimientos que contienen múltiples fármacos |
| CA2679712C (en) | 2007-01-08 | 2016-11-15 | Micell Technologies, Inc. | Stents having biodegradable layers |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| CN102083397B (zh) | 2008-04-17 | 2013-12-25 | 米歇尔技术公司 | 具有生物可吸收层的支架 |
| JP2011528275A (ja) | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ，インク． | 薬物送達医療デバイス |
| CA2756386C (en) | 2009-03-23 | 2019-01-15 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2010120552A2 (en) | 2009-04-01 | 2010-10-21 | Micell Technologies, Inc. | Coated stents |
| EP3366326A1 (en) | 2009-04-17 | 2018-08-29 | Micell Technologies, Inc. | Stents having controlled elution |
| EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | MEDICAL DEVICE DISPENSING MEDICINE |
| EP2531140B1 (en) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
| EP2560576B1 (en) | 2010-04-22 | 2018-07-18 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| WO2012009684A2 (en) | 2010-07-16 | 2012-01-19 | Micell Technologies, Inc. | Drug delivery medical device |
| CA2841360A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| KR20150143476A (ko) | 2013-03-12 | 2015-12-23 | 미셀 테크놀로지즈, 인코포레이티드 | 생흡수성 생체의학적 임플란트 |
| HK1222313A1 (zh) | 2013-05-15 | 2017-06-30 | Micell Technologies, Inc. | 可生物吸收的生物医学植入物 |
| RU2595818C1 (ru) * | 2015-05-25 | 2016-08-27 | Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" | Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона" |
| CN111057120B (zh) * | 2019-12-27 | 2021-04-27 | 苏州翔实医药发展有限公司 | 一种依托孕烯衍生物a及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB845442A (en) | 1956-03-22 | 1960-08-24 | Schering Ag | Manufacture of steroid compounds |
| DE1013284B (de) | 1956-03-22 | 1957-08-08 | Schering Ag | Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen |
| GB8313921D0 (en) * | 1983-05-19 | 1983-06-22 | World Health Org | Contraceptive compositions |
| DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
| DE4240806A1 (de) | 1992-12-01 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol |
| JPH07101884A (ja) | 1993-10-01 | 1995-04-18 | Sanei Gen F F I Inc | 水溶性ヘミセルロースを含有する製剤 |
| CZ187796A3 (en) | 1993-12-27 | 1997-01-15 | Akzo Nobel Nv | Pharmaceutical preparation |
| AU6614096A (en) * | 1995-07-17 | 1997-02-18 | Schering Aktiengesellschaft | Agent, for transdermal application, containing esters of 3-ketodesogestrel |
| DE19613698A1 (de) | 1995-07-17 | 1997-01-23 | Schering Ag | Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons |
| DE19531936A1 (de) * | 1995-08-17 | 1997-02-20 | Schering Ag | Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| WO1999067270A1 (en) | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| DE69901250T2 (de) | 1998-06-19 | 2002-10-17 | Akzo Nobel N.V., Arnheim/Arnhem | 7.alpha.-methyl 19-nortestosteron undecanoat mit androgenischer aktivität |
| US6180682B1 (en) | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
| TW200400041A (en) * | 2002-05-30 | 2004-01-01 | Akzo Nobel Nv | Use of new etonogestrel esters |
-
2003
- 2003-05-19 TW TW092113489A patent/TW200403065A/zh unknown
- 2003-05-22 SI SI200330679T patent/SI1513861T1/sl unknown
- 2003-05-22 CN CNB038123754A patent/CN1314701C/zh not_active Expired - Fee Related
- 2003-05-22 HR HRP20041101 patent/HRP20041101A2/xx not_active Application Discontinuation
- 2003-05-22 NZ NZ536619A patent/NZ536619A/en unknown
- 2003-05-22 DE DE60310714T patent/DE60310714T2/de not_active Expired - Lifetime
- 2003-05-22 PT PT03735713T patent/PT1513861E/pt unknown
- 2003-05-22 BR BR0311254-3A patent/BR0311254A/pt not_active IP Right Cessation
- 2003-05-22 ES ES03735713T patent/ES2277085T3/es not_active Expired - Lifetime
- 2003-05-22 KR KR10-2004-7019330A patent/KR20050009723A/ko not_active Ceased
- 2003-05-22 CA CA2487722A patent/CA2487722C/en not_active Expired - Fee Related
- 2003-05-22 UA UA20041109287A patent/UA80126C2/uk unknown
- 2003-05-22 AU AU2003238081A patent/AU2003238081B2/en not_active Ceased
- 2003-05-22 PL PL03373855A patent/PL373855A1/xx unknown
- 2003-05-22 WO PCT/EP2003/050187 patent/WO2003102012A2/en not_active Ceased
- 2003-05-22 AT AT03735713T patent/ATE349458T1/de not_active IP Right Cessation
- 2003-05-22 US US10/516,402 patent/US7323454B2/en not_active Expired - Lifetime
- 2003-05-22 MX MXPA04011797A patent/MXPA04011797A/es active IP Right Grant
- 2003-05-22 DK DK03735713T patent/DK1513861T3/da active
- 2003-05-22 EP EP03735713A patent/EP1513861B1/en not_active Expired - Lifetime
- 2003-05-22 CN CNA2007101028610A patent/CN101100480A/zh active Pending
- 2003-05-22 RU RU2004138807/15A patent/RU2325910C2/ru not_active IP Right Cessation
- 2003-05-22 JP JP2004509703A patent/JP4716726B2/ja not_active Expired - Fee Related
- 2003-05-22 RS YU97604A patent/RS97604A/sr unknown
- 2003-05-28 AR ARP030101859A patent/AR040130A1/es unknown
- 2003-05-28 PE PE2003000517A patent/PE20040068A1/es not_active Application Discontinuation
-
2004
- 2004-11-08 IL IL16508704A patent/IL165087A0/xx unknown
- 2004-11-10 NO NO20044898A patent/NO20044898L/no not_active Application Discontinuation
- 2004-11-15 IS IS7528A patent/IS2421B/is unknown
- 2004-12-22 CO CO04127949A patent/CO5631449A2/es not_active Application Discontinuation
- 2004-12-23 ZA ZA200410410A patent/ZA200410410B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5631449A2 (es) | Nuevos esteres de etonogestrel | |
| NZ503890A (en) | Oral contraceptives comprising non-uterotrophic anti-estrogens and progestin | |
| BRPI0512991A (pt) | uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto | |
| AR018109A1 (es) | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA | |
| BR9510550A (pt) | Compostos com ação antagonista de progesterona e antiestrogénio para utilização combinada para a contracepção feminina | |
| BR0015567A (pt) | Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos | |
| CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
| ES2128369T3 (es) | Procedimiento para la fabricacion de formas farmaceuticas solidas con liberacion prolongada en dos etapas. | |
| ATE161712T1 (de) | Desodorierende wirkstoffe | |
| BR9808888A (pt) | Formas de dosagem e método de melhorar disfunção erétil masculina | |
| ES2174920T3 (es) | Producto de combinacion para la contracepcion que contiene agentes antagonistas de progesterona y un agente gestageno. | |
| AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
| MY128021A (en) | Sheet with oil ingredient-containing layer | |
| ES2185711T3 (es) | 1,4-benzotiazepina-1,1-dioxidoshipolipimemicos. | |
| BR9612207A (pt) | Processo e kit para contracepções em mamíferos fêmeas consistindo de uma combinação de gestageno e estrogênio | |
| CO5160247A1 (es) | Composicion que cura heridas, antibacteriana bioadhesiva | |
| BR0113376A (pt) | Uso de um éster de testosterona, método de tratamento de distúrbios de insuficiência de androgênio, e, sistema de liberação de droga para contracepção masculina | |
| BRPI0512993A (pt) | uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto | |
| BR0209283A (pt) | Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme | |
| CO5670360A2 (es) | Dispositivo de retencion gastrico expandible | |
| ES2180737T3 (es) | Conjugado para la dosificacion individual de medicamentos, su procedimiento de preparacion y su uso en los mismos. | |
| ES2147453T3 (es) | Antagonistas de adenosina, procedimiento para su preparacion y su uso como medicamentos. | |
| AR001078A1 (es) | Forma farmacéutica destinada a la cesión de colagenasa en heridas y procedimiento para su elaboración | |
| MX2024009584A (es) | Metodos anticonceptivos con efectos de sangrado programado. | |
| ES2151922T3 (es) | Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |